National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders

Dennis S. Charney, Charles Nemeroff, Lydia Lewis, Sally K. Laden, Jack M. Gorman, Eugene M. Laska, Michael Borenstein, Charles L. Bowden, Arthur Caplan, Graham J. Emslie, Dwight L. Evans, Barbara Geller, Lenore E. Grabowski, Jay Herson, Ned H. Kalin, Paul E. Keck, Irving Kirsch, K. Ranga R Krishnan, David J. Kupfer, Robert W. MakuchFranklin G. Miller, Herbert Pardes, Robert Post, Mildred M. Reynolds, Laura Roberts, Jerrold F. Rosenbaum, Donald L. Rosenstein, David R. Rubinow, A. John Rush, Neal D. Ryan, Gary S. Sachs, Alan F. Schatzberg, Susan Solomon

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

A consensus conference on the use of placebo in mood disorder studies consisted of expert presentations on bioethics, biostatistics, unipolar depression, and bipolar disorder. Work groups considered evidence and presented statements to the group. Although it was not possible to write a document for which there was complete agreement on all issues, the final document incorporated input from all authors. There was consensus that placebo has a definite role in mood disorder studies. Findings of equivalence between a new drug and standard treatment in active control studies is not evidence of efficacy unless the new drug is also significantly more effective than placebo. Add-on studies in which patients are randomized to standard therapy plus the investigational drug or standard therapy plus placebo are especially indicated for high-risk patients. Mood disorders in elderly and pediatric patients are understudied, and properly designed trials are urgently needed. Research is needed on the ethical conduct of studies to limit risks of medication-free intervals and facilitate poststudy treatment. Patients must fully understand the risks and lack of individualized treatment involved in research.

Original languageEnglish
Pages (from-to)262-270
Number of pages9
JournalArchives of General Psychiatry
Volume59
Issue number3
StatePublished - Mar 20 2002
Externally publishedYes

Fingerprint

Mood Disorders
Consensus
Placebos
Clinical Trials
Biostatistics
Investigational Drugs
Therapeutics
Bioethics
Depressive Disorder
Bipolar Disorder
Research
Pharmaceutical Preparations
Pediatrics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders. / Charney, Dennis S.; Nemeroff, Charles; Lewis, Lydia; Laden, Sally K.; Gorman, Jack M.; Laska, Eugene M.; Borenstein, Michael; Bowden, Charles L.; Caplan, Arthur; Emslie, Graham J.; Evans, Dwight L.; Geller, Barbara; Grabowski, Lenore E.; Herson, Jay; Kalin, Ned H.; Keck, Paul E.; Kirsch, Irving; Krishnan, K. Ranga R; Kupfer, David J.; Makuch, Robert W.; Miller, Franklin G.; Pardes, Herbert; Post, Robert; Reynolds, Mildred M.; Roberts, Laura; Rosenbaum, Jerrold F.; Rosenstein, Donald L.; Rubinow, David R.; John Rush, A.; Ryan, Neal D.; Sachs, Gary S.; Schatzberg, Alan F.; Solomon, Susan.

In: Archives of General Psychiatry, Vol. 59, No. 3, 20.03.2002, p. 262-270.

Research output: Contribution to journalArticle

Charney, DS, Nemeroff, C, Lewis, L, Laden, SK, Gorman, JM, Laska, EM, Borenstein, M, Bowden, CL, Caplan, A, Emslie, GJ, Evans, DL, Geller, B, Grabowski, LE, Herson, J, Kalin, NH, Keck, PE, Kirsch, I, Krishnan, KRR, Kupfer, DJ, Makuch, RW, Miller, FG, Pardes, H, Post, R, Reynolds, MM, Roberts, L, Rosenbaum, JF, Rosenstein, DL, Rubinow, DR, John Rush, A, Ryan, ND, Sachs, GS, Schatzberg, AF & Solomon, S 2002, 'National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders', Archives of General Psychiatry, vol. 59, no. 3, pp. 262-270.
Charney, Dennis S. ; Nemeroff, Charles ; Lewis, Lydia ; Laden, Sally K. ; Gorman, Jack M. ; Laska, Eugene M. ; Borenstein, Michael ; Bowden, Charles L. ; Caplan, Arthur ; Emslie, Graham J. ; Evans, Dwight L. ; Geller, Barbara ; Grabowski, Lenore E. ; Herson, Jay ; Kalin, Ned H. ; Keck, Paul E. ; Kirsch, Irving ; Krishnan, K. Ranga R ; Kupfer, David J. ; Makuch, Robert W. ; Miller, Franklin G. ; Pardes, Herbert ; Post, Robert ; Reynolds, Mildred M. ; Roberts, Laura ; Rosenbaum, Jerrold F. ; Rosenstein, Donald L. ; Rubinow, David R. ; John Rush, A. ; Ryan, Neal D. ; Sachs, Gary S. ; Schatzberg, Alan F. ; Solomon, Susan. / National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders. In: Archives of General Psychiatry. 2002 ; Vol. 59, No. 3. pp. 262-270.
@article{10139f93add8438e927e1166c610eabf,
title = "National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders",
abstract = "A consensus conference on the use of placebo in mood disorder studies consisted of expert presentations on bioethics, biostatistics, unipolar depression, and bipolar disorder. Work groups considered evidence and presented statements to the group. Although it was not possible to write a document for which there was complete agreement on all issues, the final document incorporated input from all authors. There was consensus that placebo has a definite role in mood disorder studies. Findings of equivalence between a new drug and standard treatment in active control studies is not evidence of efficacy unless the new drug is also significantly more effective than placebo. Add-on studies in which patients are randomized to standard therapy plus the investigational drug or standard therapy plus placebo are especially indicated for high-risk patients. Mood disorders in elderly and pediatric patients are understudied, and properly designed trials are urgently needed. Research is needed on the ethical conduct of studies to limit risks of medication-free intervals and facilitate poststudy treatment. Patients must fully understand the risks and lack of individualized treatment involved in research.",
author = "Charney, {Dennis S.} and Charles Nemeroff and Lydia Lewis and Laden, {Sally K.} and Gorman, {Jack M.} and Laska, {Eugene M.} and Michael Borenstein and Bowden, {Charles L.} and Arthur Caplan and Emslie, {Graham J.} and Evans, {Dwight L.} and Barbara Geller and Grabowski, {Lenore E.} and Jay Herson and Kalin, {Ned H.} and Keck, {Paul E.} and Irving Kirsch and Krishnan, {K. Ranga R} and Kupfer, {David J.} and Makuch, {Robert W.} and Miller, {Franklin G.} and Herbert Pardes and Robert Post and Reynolds, {Mildred M.} and Laura Roberts and Rosenbaum, {Jerrold F.} and Rosenstein, {Donald L.} and Rubinow, {David R.} and {John Rush}, A. and Ryan, {Neal D.} and Sachs, {Gary S.} and Schatzberg, {Alan F.} and Susan Solomon",
year = "2002",
month = "3",
day = "20",
language = "English",
volume = "59",
pages = "262--270",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders

AU - Charney, Dennis S.

AU - Nemeroff, Charles

AU - Lewis, Lydia

AU - Laden, Sally K.

AU - Gorman, Jack M.

AU - Laska, Eugene M.

AU - Borenstein, Michael

AU - Bowden, Charles L.

AU - Caplan, Arthur

AU - Emslie, Graham J.

AU - Evans, Dwight L.

AU - Geller, Barbara

AU - Grabowski, Lenore E.

AU - Herson, Jay

AU - Kalin, Ned H.

AU - Keck, Paul E.

AU - Kirsch, Irving

AU - Krishnan, K. Ranga R

AU - Kupfer, David J.

AU - Makuch, Robert W.

AU - Miller, Franklin G.

AU - Pardes, Herbert

AU - Post, Robert

AU - Reynolds, Mildred M.

AU - Roberts, Laura

AU - Rosenbaum, Jerrold F.

AU - Rosenstein, Donald L.

AU - Rubinow, David R.

AU - John Rush, A.

AU - Ryan, Neal D.

AU - Sachs, Gary S.

AU - Schatzberg, Alan F.

AU - Solomon, Susan

PY - 2002/3/20

Y1 - 2002/3/20

N2 - A consensus conference on the use of placebo in mood disorder studies consisted of expert presentations on bioethics, biostatistics, unipolar depression, and bipolar disorder. Work groups considered evidence and presented statements to the group. Although it was not possible to write a document for which there was complete agreement on all issues, the final document incorporated input from all authors. There was consensus that placebo has a definite role in mood disorder studies. Findings of equivalence between a new drug and standard treatment in active control studies is not evidence of efficacy unless the new drug is also significantly more effective than placebo. Add-on studies in which patients are randomized to standard therapy plus the investigational drug or standard therapy plus placebo are especially indicated for high-risk patients. Mood disorders in elderly and pediatric patients are understudied, and properly designed trials are urgently needed. Research is needed on the ethical conduct of studies to limit risks of medication-free intervals and facilitate poststudy treatment. Patients must fully understand the risks and lack of individualized treatment involved in research.

AB - A consensus conference on the use of placebo in mood disorder studies consisted of expert presentations on bioethics, biostatistics, unipolar depression, and bipolar disorder. Work groups considered evidence and presented statements to the group. Although it was not possible to write a document for which there was complete agreement on all issues, the final document incorporated input from all authors. There was consensus that placebo has a definite role in mood disorder studies. Findings of equivalence between a new drug and standard treatment in active control studies is not evidence of efficacy unless the new drug is also significantly more effective than placebo. Add-on studies in which patients are randomized to standard therapy plus the investigational drug or standard therapy plus placebo are especially indicated for high-risk patients. Mood disorders in elderly and pediatric patients are understudied, and properly designed trials are urgently needed. Research is needed on the ethical conduct of studies to limit risks of medication-free intervals and facilitate poststudy treatment. Patients must fully understand the risks and lack of individualized treatment involved in research.

UR - http://www.scopus.com/inward/record.url?scp=0036195182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036195182&partnerID=8YFLogxK

M3 - Article

C2 - 11879164

AN - SCOPUS:0036195182

VL - 59

SP - 262

EP - 270

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 3

ER -